Vical's CMV vaccine misses in kidney transplant study

Vical Inc. (NASDAQ:VICL) and partner Astellas Pharma Inc. (Tokyo:4503) said ASP0113 missed the primary endpoint in a Phase II study to prevent cytomegalovirus reactivation in kidney transplant patients receiving an organ from a CMV-seropositive donor. Compared with placebo, the vaccine did not significantly reduce the proportion of patients with CMV viremia defined as a plasma viral load of at least 1000 IU/mL through one year.

In 4Q16, the companies expect data from an ongoing Phase III study of ASP0113 in hematopoietic cell transplant (HCT) recipients. ...